Lumos Diagnostics Expands Reach in the U.S. with National Contract for FebriDx

2 min read | September 25, 2024 06:05 PM AEST | By Team Kalkine Media

Google News:

Lumos Diagnostics Expands Reach in the U.S. with National Contract for FebriDx — Image source: Shutterstock

Recent News

Santos (ASX:STO) After the Takeover Collapse: Bargain or Value Trap?

Why Pro Medicus (ASX:PME) Is Leading the Growth Stock Conversation

Is 360 (ASX:360) Amid ASX 200 Revealing Growth’s New Reality?

Why 360 (ASX:360) ASX 200 Is Facing a New Growth Test

Make Kalkine Media
My Trusted Source

Highlights

Lumos Diagnostics secures a national contract with MediGroup for its FebriDx test in the U.S.

FebriDx delivers results in 10 minutes using a fingerstick blood sample, aiding quick diagnosis.

Lumos shares increased by 10.29% following the contract announcement, trading at 3.7 cents.

Lumos Diagnostics Holdings Ltd (ASX:LDX) has announced a significant milestone for its point-of-care respiratory test, FebriDx, following the awarding of a national contract with MediGroup. This development will enable the FebriDx test to reach a broader audience in the United States, enhancing access to its rapid diagnostic capabilities.

The FebriDx test stands out by delivering results in just 10 minutes using a simple fingerstick blood sample. This rapid turnaround is crucial for medical professionals, especially in emergency and urgent care settings, where quick decisions are essential for patient management. The recent clearance from the U.S. Food and Drug Administration (FDA) in July 2023 solidified FebriDx’s status as an approved diagnostic tool for bacterial acute respiratory infections, differentiating between bacterial and non-bacterial causes.

The collaboration with MediGroup, which encompasses over 30,000 members including surgical clinics, non-acute care facilities, and physician offices, positions Lumos well within the healthcare landscape. Doug Ward, CEO and Managing Director of Lumos, expressed optimism regarding this partnership, highlighting its importance in expanding distribution coverage for FebriDx.

Following this announcement, Lumos shares experienced a notable rise, trading at 3.7 cents, reflecting a 10.29% increase since the market opened.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.